Koichiro Matsumura

Dr. Koichiro Matsumura

Department of Medicine II, Kansai Medical University
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2019 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
MOMunemitsu Otagaki
Munemitsu Otagaki
KMKoichiro Matsumura
Koichiro Matsumura
HKHiromi Kin
Hiromi Kin
KFKenichi Fujii
Kenichi Fujii
HSHiroki Shibutani
Hiroki Shibutani
ISIchiro Shiojima
Ichiro Shiojima

4 March 2014 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
KMKoichiro Matsumura
Koichiro Matsumura
RGRubine Gevorgyan
Rubine Gevorgyan
DMDaniel Mangels
Daniel Mangels
RMReza Masoomi
Reza Masoomi
MMMohammad Khalid Mojadidi
Mohammad Khalid Mojadidi
JTJonathan Tobis
Jonathan Tobis

25 April 2019 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
KNKoichi Nagashima
Koichi Nagashima
THTakafumi Hiro
Takafumi Hiro
DFDaisuke Fukamachi
Daisuke Fukamachi
YOYasuo Okumura
Yasuo Okumura
IWIchiro Watanabe
Ichiro Watanabe
MSMorio Shoda
Morio Shoda
Aims: Anomalous origin of the coronary artery (AOCA) with an inter-arterial course (IAC) between the great vessels poses a risk for a life-threatening cardiovascular event. We assessed, in a registry-based study, the clinical features, treatment strategies, and prognoses of life-threatening cardiovascular events ensuant to AOCA. Methods and results: Included were 65 AOCA patients (48 men/17 women, aged 41 ± 23 years) from 40 clinical centres who had experienced sudden cardiac arrest (SCA) (n = 30), acute myocardial infarction (AMI) (n = 5), angina (n = 23), or syncope (n = 7). The anomalous vessel was the right coronary artery in 72% of patients and left coronary artery in 28%; the ostium was slit-like in 42%. Coronary luminal narrowing ≥75% was absent in patients with SCA or syncope (86% and 57%, respectively), but occlusion or narrowing was seen in those with AMI (100%) or angina (52%). Age ≤40 years, male sex, sporting activity, absence of prodromal symptoms, acutely angled (≤30°) take-off from the aorta, and absence of luminal narrowing of the IAC segment were associated with SCA in this patient group. Coronary vasospasm was inducible in 12 of 17 patients without coronary narrowing. Management included surgical revascularization (n = 26) percutaneous coronary intervention (n = 9), and medical treatment (n = 26). Four SCA patients died while hospitalized; no others died during the median 5.0 (range, 1.8–7.0)-year follow-up period. Conclusions: In patients with AOCA, age ≤40 years, male sex, sporting activity, and an acute take-off angle appear to be risk factors for SCA. Appropriate management can be beneficial. Confirmation in a large-scale study is warranted.

23 September 2020 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
KMKoichiro Matsumura
Koichiro Matsumura
WTWakana Teranaka
Wakana Teranaka
HMHiroshi Matsumoto
Hiroshi Matsumoto
KFKenichi Fujii
Kenichi Fujii
STSatoshi Tsujimoto
Satoshi Tsujimoto
ISIchiro Shiojima
Ichiro Shiojima
Aims Loss of skeletal muscle mass is an important determinant associated with poor long‐term prognosis in patients with acute decompensated heart failure (ADHF). However, limited evidence is available. This study investigated the prognostic value of the psoas muscle mass index (PMI) in patients with ADHF. Methods and results A total of 210 consecutive patients aged ≥60 years with ADHF were enrolled using a prospective database between 2015 and 2017. Primary endpoint was incidence of cardiac death. Cross‐sectional psoas muscle area at the L3 vertebral level was obtained by computed tomography, and PMI was calculated by height. Reduced PMI was defined as a PMI below the 25th sex‐specific percentile. Patients were also classified by their left ventricular ejection fraction (EF) as having either heart failure with a reduced ejection fraction (HFrEF, EF < 50%) or heart failure with a preserved ejection fraction (HFpEF, EF ≥ 50%). The median follow‐up period was 1.8 years. There were 44 cardiac deaths (21%) during the study period. Patients with reduced PMI had significantly higher cardiac death rates than those with preserved PMI (33% vs. 17%, log‐rank test P = 0.006). In subgroup analysis, HFpEF patients with reduced PMI had significantly higher cardiac death rates than those with preserved PMI (38% vs. 16%, log‐rank test P = 0.006); conversely, HFrEF patients had comparable cardiac death rates regardless of their PMI group (27% for reduced PMI vs. 18% for preserved PMI, log‐rank test P = 0.24). Multivariate Cox proportional hazards model revealed that patients with reduced PMI had a 2.3‐fold higher risk of cardiac death compared with patients with preserved PMI (95% confidence interval 1.23–4.42, P = 0.01). Conclusions Reduced PMI helps to predict long‐term outcome in patients with HFpEF but not HFrEF.

13 November 2019 in Cardiovascular Ultrasound
Verified
Journal Article
Open access
PDF file
KMKoichiro Matsumura
Koichiro Matsumura
TSTetsuro Sugiura
Tetsuro Sugiura
A high incidence of left ventricular diastolic dysfunction and increased risk of cardiovascular events have been reported in patients with diabetes mellitus. Sodium glucose cotransporter 2 (SGLT2) inhibitors selectively inhibit kidney glucose and sodium reabsorption, and cardiovascular benefits of SGLT2 inhibitors beyond other antidiabetic drugs have been reported in type 2 diabetes mellitus (T2DM) clinical trials. However, underlying mechanisms contributing to the improvement of cardiovascular outcomes have not been clearly identified. In this review, likely mechanisms of SGLT2 inhibitors contributing to a favorable cardiovascular outcomes are discussed based on experimental and clinical studies on cardiac function.

6 October 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
HMHiroshi Matsumoto
Hiroshi Matsumoto
KMKoichiro Matsumura
Koichiro Matsumura
YYYoshihiro Yamamoto
Yoshihiro Yamamoto
KFKenichi Fujii
Kenichi Fujii
STSatoshi Tsujimoto
Satoshi Tsujimoto
ISIchiro Shiojima
Ichiro Shiojima
Background: Muscle wasting is an important predictor of long‐term outcome in patients with cardiovascular disease, but the prognostic value of muscle wasting in patients with non‒ST‐segment‒elevation myocardial infarction is not established. The aim of this study is to investigate the prognostic value of muscle wasting, defined by psoas muscle mass index (PMI), in patients with non‒ST‐segment‒elevation myocardial infarction. Methods and Results: A total of 132 consecutive patients with non‒ST‐segment‒elevation myocardial infarction were prospectively enrolled between 2015 and 2018. Primary end point was incidence of cardiovascular events including cardiovascular deaths, non‐fatal myocardial infarction, or non‐fatal stroke. Cross‐sectional area of the psoas muscle at the L3 vertebral level was obtained by computed tomography and PMI was calculated. The median follow‐up period was 2.4 years (interquartile range, 1.1–4.0 years). There were 45 cardiovascular events (34%) during the study periods. The optimal cutoff value of PMI to predict cardiovascular events was 772 mm 2 /m 2 , as assessed by receiver operating curve analysis. Patients with reduced PMI (PMI<772 mm 2 /m 2 ) had significantly higher cardiovascular events than those with preserved PMI (PMI≥772 mm 2 /m 2 ) (48% versus 21%; log‐rank test P <0.001). Multivariate Cox proportional hazards model revealed that reduced PMI was a statistically significant predictor of cardiovascular events (hazard ratio, 3.30; 95% CI, 1.70–6.40; P <0.001). Conclusions: Muscle wasting defined as PMI is a simple and useful objective marker to predict future cardiovascular outcome in patients with non‒ST‐segment‒elevation myocardial infarction. Registration Information: URL: https://www.umin.ac.jp/ctr/ ; Unique identifier: UMIN000013445.